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Use of the mammalian target of rapamycin (mTOR) inhibitor
rapamycin in organ transplantation has evolved through
different phases over the past two decades. After its
discovery in the mid 1970s, antifungal and cytotoxic effects
were the first of its properties to be explored, but the most
significant advancement was found in its use as an
immunosuppressive agent to reduce transplant rejection.
This was viewed as an important step forward for
immunosuppression, as early studies suggested that
rapamycin was less nephrotoxic than calcineurin inhibitors
(CNIs). Later, detrimental effects of rapamycin on kidney
function were found in some patients. Nonetheless, a
fascination with the mTOR pathway and its central role in
multiple cellular processes has ensued. Among the potential
positive clinically relevant effects is rapamycin’s capacity
to interfere with fibrotic processes that often accompany
transplant rejection, and to influence the preferential
development of immunological tolerance. A feature of
increasing importance is that the mTOR pathway is central
for vital aspects of tumor development, including
angiogenesis and cell growth; rapamycin, therefore, has
anticancer activities, which may prove critical in the fight
against high cancer rates in transplant recipients. The final
chapters defining the value of rapamycin have not been
written yet, and indeed remain a work in progress. Only
further research will reveal the full potential of rapamycin in
organ transplantation.
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EARLY VERSUS MORE RECENT IMPRESSIONS OF
RAPAMYCIN USE IN TRANSPLANTATION
Rapamycin was first discovered in the early 1970s from a soil
sample taken on Easter Island (Rapa Nui). Based on the
molecule’s readily apparent antiproliferative effects, it was first
tested as an antimicrobial agent and for its cytotoxicity against
tumors when used at high concentrations.1 However, its actual
medicinal potential was not revealed until used continuously at
low concentrations as an immunosuppressant in organ
transplantation. Several pharmacological rapamycin analogs
(e.g., sirolimus and CCI-779 (Pfizer, New York, NY, USA),
RAD001 (Novartis, Basel, CH, USA), AP23573 (Ariad Pharma,
Cambridge, MA, USA)) have been developed, as a result, all of
which will simply be hereafter referred to as ‘rapamycin’.
Regarding its use as an immunosuppressant, it was discovered
early that T cells are inhibited by rapamycin as interleukin-2
triggers T-cell proliferation via the mammalian target of
rapamycin (mTOR) signaling pathway. Expectations became
increasingly high that this new immunosuppressive drug would
be effective at preventing rejection, although not causing
nephrotoxicity associated with calcineurin inhibitors (CNIs)
use. Early animal experiments supported this notion, and
initial clinical studies also pointed towards reduced nephro-
toxicity with rapamycin use.2 Studies that followed, however,
where rapamycin was clinically tested to reduce or eliminate
CNI use, particularly in the setting of delayed or chronic renal
allograft dysfunction, showed that mTOR inhibition can, in
some patients, cause proteinuria.3 The exact effects of mTOR
inhibition on cells of the kidney are not completely understood,
but evidence suggests that tubular cell regeneration is affected,
as well as podocytes.4 Interestingly, podocytes produce vascular
endothelial cell growth factor, which is an important factor for
maintaining the glomerular filtration barrier; as rapamycin
potently inhibits vascular endothelial cell growth factor gene
transcription and signaling,5 proteinuria could be a conse-
quence of its therapeutic use. With proper monitoring and
patient selection criteria, proteinuria is avoidable or con-
trollable in most cases with rapamycin use; in more malignant
proteinuria situations, rapamycin use needs to be withdrawn.
The question of rapamycin effectiveness against rejection
also must be considered. In renal transplantation, rapamycin
has proved quite effective against kidney rejection when used
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de novo in combination with CNIs, but to avoid excessive side
effects, both substances need to be used at reduced levels.
Although an improvement in glomerular filtration rate is
reproducible when CNIs are tapered away,6 the trade-off is
that rejection rates may increase. An alternative approach
gaining more favor recently is to convert CNI-based
immunosuppression to an mTOR inhibitor-based regimen
at strategic periods within the first year after transplantation.
Early clinical data suggest that this option does not increase
rejection rates, improves renal function,7 and provides some
protection against chronic allograft nephropathy.8 To date,
however, the issue of whether rapamycin use alone can
adequately prevent rejection and improve long-term renal
allograft function remains an open question, and is beyond
the scope of debate within this concise review.
MOLECULAR INTRIGUE
Perhaps the most fascinating aspect related to rapamycin is
the central significance of the mTOR pathway, which it
influences. Indeed, the past decade of research on the mTOR
pathway has revealed its pivotal role in controlling responses
to a wide variety of growth factors, cytokines (e.g.,
interleukin-2), and nutrients. Recent studies indicate that
even life span is affected (positively) by mimicking dietary
restriction.9 Through the mTOR axis, basic cellular processes
such as cell growth and proliferation are regulated, control-
ling the behavior and development of normal as well as
abnormal tissues. In some instances it becomes even more
complex because common processes such as angiogenesis are
dependent on mTOR signaling, affecting both normal tissue
repair (e.g., wound healing) and pathological tumor expan-
sion. It is not surprising, therefore, that mTOR is highly
regulated and integrated with other intracellular signaling
pathways. The complexities of this molecular pathway have
produced a high degree of molecular intrigue, motivating
researchers to investigate the more exact effects of mTOR
inhibition by rapamycin and other mTOR inhibitors.
Here, we can only highlight the most critical elements of the
mTOR signaling pathway (Figure 1). mTOR is part of two
signaling complexes, mTOR complex 1 (mTORC1) and
mTORC2. Interestingly, AKT provides signals to mTORC1,
but mTORC2 actually regulates AKT through Ser473 phos-
phorylation. This review focuses on mTORC1, as it is the
primary target of rapamycin. Phosphoinositide-dependent
kinase-1 phosphorylates AKT at a second site, Thr308, further
potentiating AKT activity. A wide variety of growth factors and
cytokines can trigger this pathway. Key upstream signaling
molecules include phosphoinositide 3-kinase, which converts
phosphatidylinositiol-4,5-phosphate to phosphatidylinositiol-
3,4,5-phosphate and recruits phosphoinositide-dependent ki-
nase-1 to AKT. Another important molecule is PTEN
(phosphatase and tensin homolog deleted on chromosome
10), which is a tumor suppressor that reverses the phosphati-
dylinositiol-4,5-phosphate-to-phosphatidylinositiol-3,4,5-phos-
phate reaction, thus reducing AKT activity. Indeed, AKT has a
critical role by mediating mTORC1 activation via inhibition of
the tumor suppressors, hamartin tuberous sclerosis complex
(TSC)1) and tuberin (TSC2). The TSC1/2 complex inactivates
Rheb (Ras homolog enriched in brain), thereby inhibiting
mTORC1 activation. The primary downstream effectors of
mTORC1 are S6 kinase 1 and eukaryotic initiation factor
4E-binding protein-1, which are important regulators of
mRNA translation. Interestingly, to apparently protect against
overactivation of mTORC1, active S6 kinase 1 negatively feeds
back to inhibit AKT, and thus activation of mTORC1.
The mTOR pathway is tangentially influenced in many
ways. For instance, inhibitory kB kinase-b, a kinase down-
stream of tumor necrosis factor-a, integrates with mTORC1
by inhibiting TSC1/2, molecularly linking inflammation and
cell proliferation.10 The mitogen-activated protein kinase
cascade is also linked to mTOR, as inhibition of one pathway
affects the activation of the other. Additionally, mTOR,
because of its effects on cell growth, is intimately involved in
energy metabolism. For instance, mTORC1 activity is
regulated by sensing cellular adenosine triphosphate levels
(via AMP-activated protein kinase and TSC1/2) and by
sensing amino acids.11 Even lipid metabolism is influenced by






















Figure 1 |mTORC1 pathway basics. Abbreviations: eIF-4E,
eukaryotic initiation factor 4E; IKKb, inhibitory kB kinase-b;
IL-2, interleukin-2; MAPK, mitogen-activated protein kinase;
mTOR, mammalian target of rapamycin; mTORC, mTOR complex;
PC-1, polycystin-1; PDK1, phosphoinositide-dependent kinase-1;
PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin
homolog deleted on chromosome 10; Rheb, Ras homolog
enriched in brain; S6K1, S6 kinase 1; TSC, tuberous sclerosis
complex; VEGF, vascular endothelial cell growth factor; 4E-BP1,
eIF-4E-binding protein-1.
1076 Kidney International (2010) 78, 1075–1079
min i rev iew EK Geissler and HJ Schlitt: Pros of rapamycin use in organ transplantation
mTORC1, positively affecting peroxisome proliferator-activated
receptor-g, which has an important role in adipogenesis
and lipid accumulation.12 Therefore, mTOR’s central in-
tracellular signaling position in essential cell processes make
it an attractive therapeutic target for conditions where it
is desirable to reduce cell growth and proliferation (e.g.,
T cells—immune suppression, neoplastic cells—oncology,
endothelial and smooth muscle cells—vasculopathy).
DISCOVERY OF ANTITUMOR EFFECTS
Besides the well-known immunosuppressive properties of
rapamycin, there is a rapidly expanding literature base on its
anticancer effects. Although early toxicology studies showed
some modest effects on tumors, the concentrations of
rapamycin used in these experiments were high and carried
significant toxicity.1 Enthusiasm for rapamycin use as a pure
oncologic agent faded until early in the present decade. A better
understanding of the mTOR signaling pathway brought new
hypotheses as to how rapamycin could be used more effectively
against cancer. One breakthrough came in 2002 when Guba
et al.5 discovered in mice that rapamycin potently inhibits
tumor angiogenesis, and thus tumor growth, at relatively low,
sustainable, concentrations that are compatible with long-term
immunosuppression in transplant recipients. Evidence sug-
gested that the antiangiogenic effect was related to inhibition of
vascular endothelial cell growth factor production and en-
dothelial cell responses to vascular endothelial cell growth factor,
which are both dependent on the mTOR pathway. This key
finding was later confirmed by others, and tumors highly
dependent on angiogenesis have since shown positive responses
to rapamycin treatment.13,14 A natural question in the context
of organ transplantation is whether rapamycin could cause a
tumor to regress in immunosuppressed patients. Indeed, it has
been shown that rapamycin can prevent allograft rejection in
mice through its immunosuppressive effects, while at the same
time inhibiting tumor growth.15 At least in the situation of
Kaposi’s sarcoma in renal transplant recipients, this idea has
shown clinical results.13 These examples are an extraordinary
demonstration of the multiple effects of rapamycin, and they
stress the central importance of this pathway for essential
cellular processes.
The anticancer effects of rapamycin are not limited to
angiogenesis. Tumor cells are often directly dependent on the
mTOR pathway because of their need to use its proliferation-
promoting mechanisms and because gene mutations within
the pathway can constitutively activate mTOR. There are
many examples that illustrate this latter point. For example,
PTEN and TSC1/2 can be oncogenic through mutations
that result in a release of their inhibitory effects on mTORC1;
e.g., tuberous sclerosis is a specific hyperproliferative
condition that results from mutations in the tuberous
sclerosis suppressor complex. Overexpression of the receptor
tyrosine kinase human epidermal growth factor receptor 2 in
malignancies such as breast and gastric cancer is another
example of promoting pathological signaling through the
AKT/mTORC1 axis. Polycystic kidney disease is a condition
where mutations in polycystin-1 have very recently been shown
to cause a lack of tethering of TSC2 to the cell membrane,
decreasing the ability of TSC2 to repress mTORC1.16 These and
other mTORC1 pathway-promoting gene mutations make
mTOR an attractive target for antitumor therapy.
Recent studies also suggest that rapamycin has even broader
ranging effects that influence the growth and development of
tumors. For instance, rapamycin treatment markedly reduces
spontaneous de novo intestinal tumor formation in APCmin/þ
mice, with a near complete correction in the expression of
otherwise upregulated oncogenic Naþ and Kþ ion channels;17
the mechanism for the normalization of oncogenic ion
channels is unknown. Rapamycin can also strongly affect the
pattern of ultraviolet-signature p53 mutations, which are
thought to be important in skin cancer development.18
Therefore, there is even evidence that mTOR influences
processes that affect DNA damage repair. With more research
and a better understanding of the mTOR pathway, the spectrum
of rapamycin effects that may impact tumor growth will likely
continue to expand.
Finally, we cannot leave this discussion without addressing
the potential impact that rapamycin has on immunity against
tumor cells and viruses. An intuitive reaction to this point is
that rapamycin inhibits the immune system in general and
therefore must diminish immunity against invasive neo-
plasms. Although this is a reasonable argument, the
conclusion appears premature and full of complexities. In
favor of this hypothesis are two main factors, the well-known
general suppressive effect that rapamycin has on T-cell
proliferation, and its recently discovered promotion of
T-regulatory cell development.19 It can be reasonably speculated
that T-regulatory cells could act locally within a tumor, or
systemically towards a virus, to protect against invading
immune cells; much the same idea as the protection against
rejection that is expected with T-regulatory cells in a patient
with a tolerant organ allograft. Although it is concerning that
rapamycin treatment could promote immunological toler-
ance to a tumor entity or virus, there is recent data that takes
a completely opposite perspective. Rao et al.20 have recently
reported that mTOR inhibition with rapamycin inhibits T-
bet and promotes eomesodermin expression, which is
associated with an enhanced memory phenotype in CD8þ
cells; rapamycin-treated CD8þ cells showed impressive
antitumor activity in vivo. Data also suggest that rapamy-
cin-exposed CD8þ cells could work favorably against BK
virus,21 cytomegalovirus,22 or other viruses23 associated with
infectious and neoplastic diseases in transplant recipients
(e.g., Epstein–Barr virus in posttransplant lymphoprolifera-
tive disease; herpesvirus in Kaposi’s sarcoma). Indeed, a
recent organ transplantation guideline publication suggests
that there may be a lower incidence of cytomegalovirus
infections when using mTOR inhibitors.24 It has to be added,
however, that conflicting data and much controversy
surrounds this topic, so further studies will be critical in
determining the balance of effects rapamycin has on the
development of malignancies and viral infections.
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TOLERANCE-INDUCTION POTENTIAL
There is much debate about which immunosuppressive
agents and regimens may possess the most favorable proper-
ties for tolerance induction in organ transplantation. Early
experimental data indicate that CNI use, through blocking
T-cell activation, may hinder the development of immuno-
logical tolerance.25 In contrast, allowing T-cell activation, but
not proliferation, by using rapamycin could potentially
promote tolerance. Moreover, recent publications indicate
that as mTORC1 is essential for the development of
conventional effector T cells, blocking mTORC1 with
rapamycin likely favours T-regulatory cell expansion.26
Indeed, expanding T-regulatory cells either through drug
therapy or ex vivo cell therapy is being considered in novel
transplant tolerance-induction strategies. Rapamycin may
also indirectly promote T-cell anergy and regulation by
inhibiting the maturation of dendritic cells.27 However, the
immune response depending on mTOR is as complex as that
when considering its influence on tumor formation. For
instance, it has been shown that molecules involved in the
innate immune response (e.g., toll-like receptor 4) can
actually inhibit the production of inflammatory cytokines
through mTOR, thus predicting that mTOR inhibition could
be proinflammatory.28 Therefore, the timing of therapeutic
rapamycin application may be critical in determining its
potential in inducing immunological tolerance. These con-
siderations notwithstanding, mTOR has a central, albeit
complex, role in directing the immune response.
CONTROL OF FIBROTIC PROCESSES
Preventing development of interstitial renal fibrosis remains
an unsolved problem following organ transplantation.
Although we have learned how to control early and late
acute rejection reactions against allografts, chronic patholo-
gical processes such as fibrosis have not proven to be
controllable. When considering renal fibrosis, transforming
growth factor-b is a well-known primary mediator through
induction of fibroblast proliferation and myofibroblast
transition. Although smad-2 and -3 are the most commonly
known substrates of the transforming growth factor-b
receptor, recent evidence also suggests that transforming
growth factor-b signals via other pathways, including the
AKT/mTORC1 axis.29 Indeed, blocking mTORC1 with
rapamycin has been recently shown to reduce renal inter-
stitial fibrosis in an obstructive nephropathy rodent model by
diminishing the number of interstitial fibroblasts and
myofibroblasts.30 The question remains, however, whether
rapamycin can reduce fibrosis in transplant recipients. Data
have been analyzed from different trials where patients on
CNIs were later converted to rapamycin, but the results are
conflicting. Pontrelli et al.31 have reported that rapamycin
can substantially reduce interstitial fibrosis in renal transplant
recipients after a chronic allograft nephropathy diagnosis,
whereas Servais et al.32 did not find a significant reduction in
fibrosis after 1 year when patients were converted from CNIs to
rapamycin 12 weeks after renal transplantation. A number of
factors can explain the results of the latter study, as the negative
effects of CNIs can occur very early (before randomization)
and the readout was for a short period, possibly not allowing
for detection of a difference within the observed time frame.
Nonetheless, more trials testing this hypothesis will clearly need
to be performed to determine whether fibrosis can be
influenced by rapamycin following renal transplantation. We
should add to this discussion that hepatic fibrosis associated
with liver disease may also be targetable with rapamycin
treatment, as a recent experimental study in rats has
demonstrated.33 Interestingly, multiple profibrinogenic path-
ways are operable within liver tissue, suggesting that the
mechanism of rapamycin inhibition of fibrosis in the liver is
different than that which takes place in the kidney.
PITFALLS OF RAPAMYCIN USE IN TRANSPLANTATION
Although this review concentrates on the positive aspects of
rapamycin use in transplantation, it is important to include
some discussion of the pitfalls encountered with the use of
this substance or its derivatives. The most common problems
are associated with side effects that can decrease the quality of
life for some transplant recipients. In particular, oral ulcers,
skin lesions (e.g., acne) and various forms of edema can
present distressing problems for patients. In these cases, dose
reductions can be helpful, along with specific counteractive
treatments, but the problems may continue to persist and
eventually result in rapamycin discontinuation. Furthermore,
other serious side effects include wound-healing problems
after surgery, delayed graft function, anemia, pneumonitis,
and the problem described earlier with proteinuria in some
patients. These types of side effects have sometimes resulted
in elevated dropout rates in clinical studies. Although a
legitimate argument can be made that physicians prematurely
switch patients off mTOR inhibitors before making enough
efforts to manage the side effects, it is also fair to make the
argument that treatment with mTOR inhibitors requires
substantial medical management. Therefore, assessment of
the risk/benefit profile of rapamycin use in individual renal
transplant recipients has become a central, and decisive, issue.
CLINICAL PERSPECTIVES
When trying to calculate the future of rapamycin use in
organ transplantation, there are many factors that have to go
into the equation. Factors of particular importance that have
to be considered are the development of malignancy and
chronic fibrosis, both of which are critical problems facing
transplantation medicine. Based on our present knowledge of
the mTOR pathway, including experimental and clinical data
that are presently available, an argument can be made for
rapamycin treatment as a means to diminish these serious
and otherwise untreatable post-transplant complications.
Moreover, of the immunosuppressants currently available
for transplantation, rapamycin has shown the highest
potential to support the development of immunological
tolerance in experimental models, especially those that
espouse tolerance through the induction of anergy and
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T-regulatory cells. This is not an insignificant consideration,
given that the induction of at least some level of stable
immunological tolerance remains the ‘holy grail’ of trans-
plantation medicine. If future clinical trials can definitively
show that any of these potential positive attributes are
veritable, mTOR inhibitors could gain a more broader base of
acceptance in organ transplantation. The value of rapamycin
in the situation where a malignancy occurs, or has a high
probability of occurrence, in transplant recipients is especially
promising. In this respect, one important ongoing multi-
centre clinical study is testing whether rapamycin treatment
can reduce hepatocellular carcinoma-free survival in liver
transplant recipients with a pretransplant hepatocellular
carcinoma.34 Demonstration of a clear long-term benefit
from this and other ongoing or planned clinical studies will
give motivation for transplant physicians to better manage
the side effects associated with rapamycin use, rather than
prematurely switching to other immunosuppressants that
possess their own undesirable side effect profiles.
In the meantime, intrigue regarding the central role
mTOR has in multiple cellular processes will continue to
shed new light onto the potential therapeutic usefulness of
mTOR inhibitors in organ transplantation. What is known so
far is that rapamycin is a drug with potent immunosuppres-
sive, antiproliferative, and antitumor effects, indicating that
this substance influences a wide range of cell types and
cellular processes. The level of this complexity is shown by
rapamycin’s ability to treat multiple conditions simulta-
neously, as demonstrated by its combined immunosuppres-
sive and anticancer action in transplant patients with a
malignancy. The question that still needs to be answered is
whether the balance of positive effects outweighs the side
effects that often accompany treatment. Only further experi-
mental and clinical studies can answer this question.
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